Orthofix Medical is a mid-cap musculoskeletal company trying to prove that a narrower, post-merger portfolio can grow without burning cash. The second-quarter print raised full-year sales and adjusted earnings before interest, tax, depreciation, and amortization after Medicare restored pay on non-invasive bone growth stimulators. That is the first clean reimbursement reset of the Massimo Calafiore era. The equity still sits near its fifty-two-week low because the same quarter consumed cash to settle claims from three former executives and left free cash flow deeply negative for the first half.
The tension is quality versus conversion. Global Limb Reconstruction and Spine Fixation delivered double-digit constant-currency growth, and Biologics finally stopped shrinking after a year of contraction. Adjusted earnings before interest, tax, depreciation, and amortization still slipped a touch as international mix diluted the gross margin, and long-term debt jumped after a January term-loan draw. The market is being asked to pay for a mid-single-digit growth story on an enterprise value of roughly half a billion while the cash statement has not yet confirmed the income-statement repair.
Second-quarter net sales reached $211 million. Adjusted earnings before interest, tax, depreciation, and amortization printed at $20 million. That is the test the next several quarters have to answer. The open question is whether restored stimulator reimbursement and a fourth-quarter European distributor order turn those mid-single-digit sales into cash, or whether pruning the bottom fifth of United States spine distributors and a later European market-access air pocket keep the equity pinned to a distressed multiple.